Probing the binding of coumarins and cyclothialidines to DNA gyrase
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Probing the binding of coumarins and cyclothialidines to DNA gyrase. / Kampranis, S C; Gormley, N A; Tranter, R; Orphanides, G; Maxwell, A.
In: Biochemistry, Vol. 38, No. 7, 16.02.1999, p. 1967-76.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Probing the binding of coumarins and cyclothialidines to DNA gyrase
AU - Kampranis, S C
AU - Gormley, N A
AU - Tranter, R
AU - Orphanides, G
AU - Maxwell, A
PY - 1999/2/16
Y1 - 1999/2/16
N2 - DNA gyrase is the target of a number of antibacterial agents, including the coumarins and the cyclothialidines. To extend our understanding of the mechanism of action of these compounds, we have examined the previously published crystal structures of the complexes between the 24 kDa fragment of GyrB and coumarin and cyclothialidine drugs and made mutations by site-directed mutagenesis. We used proteolysis as a probe of drug binding to wild-type and mutant proteins. Limited proteolysis of gyrase revealed that binding of these antibiotics is associated with a characteristic proteolytic fingerprint, suggesting a drug-induced conformational change. The ability of the mutants to bind the drugs was studied by testing their ability to induce the coumarin-associated proteolytic signature and to bind to a novobiocin-affinity column. To analyze further the interaction of the drugs with gyrase, we studied the binding using surface plasmon resonance. Mutation of Asn46 to Asp has only a modest effect on the binding of coumarins, while an Asn46 to Leu mutation results in a 10-fold decrease in the affinity. Mutation of Asp73 to Asn completely abolishes binding to both coumarins and cyclothialidines. Mutations at these residues also abolish ATP hydrolysis, explaining the inability of such mutations to occur spontaneously.
AB - DNA gyrase is the target of a number of antibacterial agents, including the coumarins and the cyclothialidines. To extend our understanding of the mechanism of action of these compounds, we have examined the previously published crystal structures of the complexes between the 24 kDa fragment of GyrB and coumarin and cyclothialidine drugs and made mutations by site-directed mutagenesis. We used proteolysis as a probe of drug binding to wild-type and mutant proteins. Limited proteolysis of gyrase revealed that binding of these antibiotics is associated with a characteristic proteolytic fingerprint, suggesting a drug-induced conformational change. The ability of the mutants to bind the drugs was studied by testing their ability to induce the coumarin-associated proteolytic signature and to bind to a novobiocin-affinity column. To analyze further the interaction of the drugs with gyrase, we studied the binding using surface plasmon resonance. Mutation of Asn46 to Asp has only a modest effect on the binding of coumarins, while an Asn46 to Leu mutation results in a 10-fold decrease in the affinity. Mutation of Asp73 to Asn completely abolishes binding to both coumarins and cyclothialidines. Mutations at these residues also abolish ATP hydrolysis, explaining the inability of such mutations to occur spontaneously.
KW - Adenosine Triphosphate
KW - Arginine
KW - Asparagine
KW - Aspartic Acid
KW - Binding Sites
KW - Coumarins
KW - DNA Topoisomerases, Type II
KW - Enzyme Inhibitors
KW - Hydrolysis
KW - Kinetics
KW - Mutagenesis, Site-Directed
KW - Peptides, Cyclic
KW - Surface Plasmon Resonance
KW - Topoisomerase II Inhibitors
KW - Trypsin
U2 - 10.1021/bi982320p
DO - 10.1021/bi982320p
M3 - Journal article
C2 - 10026280
VL - 38
SP - 1967
EP - 1976
JO - Biochemistry
JF - Biochemistry
SN - 0006-2960
IS - 7
ER -
ID: 159085568